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Background: To determine whether cortisol secretion and glucocorticoid receptors in lymphocytes and monocytes
are altered in patients with impaired glucose tolerance, and whether treatment with a hypocaloric diet and
metformin could interfere with these aspects.
Methods: This is an analytical, interventional, case series study. Patients with impaired glucose tolerance were
included. They received 500 mg of metformin twice daily and followed a low glycemic index diet for 16 weeks.
Cortisol levels were assessed at 8:00 A.M. before and after use of 0.25 mg of dexamethasone at 11:00 P.M. the day
before.
Results: Sixteen subjects (9 men) were included. Normal basal levels of cortisol and adequate responses to the low
dose of dexamethasone were observed before and after treatment. There was no significant correlation between
the parameters evaluated and cortisol levels. Nevertheless, there was a strong correlation between the number of
glucocorticoid receptors, BMI (r = 0.88; p = 0.02), and insulin AUC (r = 0.94; p = 0.005) before treatment; after
treatment, all these associations ceased to exist.
Conclusion: The cortisol secretion remained normal in the group of patients with impaired glucose tolerance.
Treatment with metformin and diet did not change this condition. However, glucocorticoid receptor number had a
strong correlation with insulin, due to insulin resistance, but this characteristic was lost after treatment.
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Type-2 diabetes mellitus generally affects overweight or
obese individuals over 40 years old. These patients have
insulin resistance and deficiency [1]. However, before
type-2 diabetes mellitus is established, individuals may
show the following pre-diabetic conditions: impaired fast-
ing glucose between 100 mg/dl and 125 mg/dl, and im-
paired glucose tolerance two hours after an oral glucose* Correspondence: lacasulari@unb.br
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199 mg/dL [1].
Lifestyle changes with adequate nutrition and increased
physical activity, with or without treatment with metfor-
min, can prevent or delay the onset of type-2 diabetes
mellitus [1–3]. Metformin, which is an insulin action
sensitizer, is recommended as a first-choice oral drug for
the treatment of type-2 diabetes due to its preventive ac-
tion in populations at risk [3–5].
In order to potentially prevent the onset of type-2 dia-
betes in individuals with pre-diabetic symptoms, it is im-
portant to study the characteristics involved in the
pathophysiology of this condition. A still unsettled problemis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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in patients with metabolic syndrome [6–9].
Several changes in the hypothalamic-pituitary-adrenal
(HPA) axis of subjects with abdominal obesity have been
described: changes in pulsatile secretion of adrenocorti-
cotropic hormone (ACTH), increased cortisol secretion
after laboratory stress tests, hyperresponsivity of the
HPA axis to peptides such as the corticotropin-releasing
hormone (CRH), associated or not with arginine vaso-
pressin (AVP) (for references, see [10, 11]). There is evi-
dence of peripheral and central alterations of the HPA
axis in patients with abdominal obesity [9].
The use of low doses of dexamethasone has been a
strategy to detect subtle changes in the negative feedback
of cortisol secretion in obese individuals or in those with
metabolic syndrome who are not yet diabetic. Alterations
in glucose and insulin metabolism can also be identified
[10–14]. Nonetheless, results are conflicting. In patients
with metabolic syndrome, a higher concentration of corti-
sol has been observed after treatment with dexamethasone
as compared to healthy controls [15]. In obese individuals,
cortisol response to dexamethasone was reported as nor-
mal [10, 12] or altered [14]. Very few data are available on
the effect of insulin resistance on the corticosteroid recep-
tors density [16].
The objectives of this study were to determine whether
cortisol secretion is altered in a group of patients with
pre-diabetic conditions and whether treatment with a
hypocaloric diet and metformin treatment could interfere
with this process. In addition, glucocorticoid receptors on
mononuclear cells–lymphocytes and monocytes–were
analyzed before and after treatment to determine if the
receptor expression was affected in this group of pre-
diabetic patients.
Research design and methods
Study design and ethics
This is an analytical, interventional, case series study de-
signed as a single group clinical trial in pre-diabetic sub-
jects on a hypocaloric low glycemic index diet plus
metformin. The study lasted 16 weeks with monthly
follow-up visits (total of 5 visits) to verify adhesion to
the dietary treatment, to adjust dietary prescription, and
to receive medication.
Metformin was kindly donated by Medley Laboratory,
Brazil. The dose of 1 g/day metformin was divided into
two doses (500 mg) taken at breakfast and dinner. The
subjects were instructed to start the metformin treat-
ment with 500 mg per day and after 7 days increase to
500 mg twice a day. In presence of any side effect they
were instructed to return to the single dose for 7 days
and to increase to twice a day subsequently. During the
follow-up period no subjects reported any side effect.The study protocol was approved by the Ethics Com-
mittee in Human Research of the School of Health Sci-
ences at the University of Brasília, Brazil (N. 035/2004).
All volunteers were informed of the objectives of the study
and signed a written informed consent to participate.
Subjects
Participants were recruited through public announce-
ments. Inclusion criteria were adults aged between 18
and 50 years old, of both sexes, body mass index
from 25 to 35 kg/m². Smokers, pregnant or lactating
or post-menopausal women were not included, as well
as individuals who had used medication and followed
a therapeutic diet in the last two years. Subjects with
a fasting blood glucose value higher than 126 mg/dL
and/or higher than 200 mg/dL 120 min after the start
of the OGTT were also excluded.
The sample size was determined using the software
G*Power, version 3.1.9 (Heinrich Heine University
Düsseldorf, Düsseldorf, Germany) [17], based on the result
from Tam et al. [18] considering the morning cortisol
levels as the main variable. A statistical power (1-β) of
80 % and a level of significance (α) of 5 % were considered,
which resulted in a sample of 16 subjects, as the necessary
number for this study.
All subjects had cortisol inhibition < 1.8 mg/mL at
8:00 A.M. after the ingestion of 2 mg of dexamethasone
(Decadron, Merck Sharp & Dohme, São Paulo, Brazil) at
11:00 P.M. of the previous day, thus excluding the oc-
currence of endogenous Cushing’s syndrome [19].
To evaluate the responsiveness of the hypothalamic-
pituitary-adrenal axis to low doses of dexamethasone, a
cortisol analysis was conducted after administration of
0.25 mg of dexamethasone at 11:00 P.M. and cortisol
levels were measured at 8:00 A.M..
Subjects were also submitted to an oral 75-g glucose tol-
erance test after an overnight fast. Blood samples were
collected from the antecubital vein at 0, 30, 60, 90 and
120 min for insulin and glucose measurements. Individ-
uals with baseline fasting glucose at OGTT <99 mg/dL
and >140 mg/dl and glucose levels <200 mg/dL 120 min
after the ingestion of oral glucose (impaired glucose toler-
ance) were selected [1].
Values for the homeostasis model assessment of insu-
lin resistance (HOMA2-IR), HOMA β-cell function
(HOMA2- % β), and HOMA insulin sensitivity (HOMA2-
% S) were calculated using the computer software HOMA
calculator v2.2.2 (University of Oxford; to determine insulin
resistance, β-cell function, and insulin sensitivity, respect-
ively [20, 21]. The Cederholm index (CI) was calculated to
determine peripheral insulin sensitivity [22]. The calcula-
tion, based on an appropriate analytical matrix and unified
units, has been utilized in our previous studies in obese
subject [23]. Plasma glucose concentration was expressed
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mental area under the curve (AUC) for insulin and glucose
was calculated excluding any values below the baseline
using the trapezoidal method [24].
Dietary and physical activity assessment
Dietary adherence and physical activity were assessed dur-
ing the follow-up period according to the methodology
described by the Dietary Reference Intakes (DRI) [25].
The subjects followed a hypocaloric low glycemic
index diet. Dietary energy reduction was set between 25
and 30 % of the total energy expenditure, and the dietary
macronutrient percentages were based on the acceptable
macronutrient distribution range [25]. Dietary energy
was divided into food groups according to the Brazilian
food pyramid. A glycemic index table was created and
organized into food groups. At the beginning of the
study, participants were instructed in the use of their
diet. The table was meant to help participants adhere to
the diet.
The adherence to the treatment and the diet was
checked in a monthly visit to the laboratory where a
follow-up questionnaire was administered and another
30-day card of metformin pills was given to the subjects.
They were instructed to bring the used pill card for veri-
fication. Adherence to the diet was acknowledged in
subjects who made 4–5 visits, did not ingest food that
gave them more than the proposed dietary energy and
had 4–6 meals per day. The dietary fiber intake was set-
tled to ≥ 70 % of the dietary reference intake of the DRI
[25]. Food intake was assessed by repeated 24-h recalls
in each visit. To ensure accuracy, a photograph of a food
portion guide was shown to all participants estimate the
consumed food portions. Each dietary recall was
reviewed in the presence of the participant to ensure its
accuracy and completeness. Food portions were con-
verted into grams, and total energy intake and consump-
tion of macronutrients and fiber were analyzed using the
Nutrition Data System for Research software (version
2011) (NDSR, University of Minnesota, Minneapolis,
MN, USA), which includes typical Brazilian foods pre-
pared using standardized recipes. Glycemic index of the
diets were calculated to be below 60.
The level of physical activity was assessed using a
short-version of the international physical activity ques-
tionnaire, and total energy expenditure was estimated by
adding the appropriate physical activity level (PAL) to
the equations published by the DRI [25].
Anthropometric and body composition assessment
Body weight was assessed using an electronic platform
scale ranging from 0 to 150 kg and precision of 0.1 Kg;
height was measured using a scientific stadiometer ran-
ging from 0 to 210 cm and precision of 0.1 cm. BMI wascalculated [(body weight (Kg) / height (m2)] and classi-
fied according to parameters established by the World
Health Organization [26]. Waist circumference was mea-
sured at the midline between the lowest rib and the iliac
crest with precision of 0.1 cm. Body fat percentage was
calculated by using a tetrapolar electrical bioimpedance
measurement (Bioelectrical Impedance Analysis (BIA)
Test–Quantum II RJL® Portable Body Fat Analyzer,
USA) [27]. All measurements and classifications were
done according to standardized protocols always by the
same investigator.
Biochemical analysis
Fasting state was verified using a glucometer (Roche
Diagnostics, Mannheim, Germany) in capillary blood
samples. Blood samples drawn in the OGTT or post dexa-
methasone tests were centrifuged and serum separated.
Serum insulin levels were measured by chemiluminescence
(Elecsys 2010, Roche Diagnostics, Mannheim, Germany),
glucose by oxidasis-GOD/POD-automatized (Immulite
2000, DPC, Los Angeles, USA), cortisol by electrochemilu-
minescence (Elecsys 2010, Roche Diagnostics, Mannheim,
Germany), total cholesterol, high density lipoprotein
(HDL), and triacylglycerol by enzymatic colorimetric kits
(Labtest Diagnostica S.A., Belo Horizonte, Brazil). LDL-
cholesterol and VLDL-cholesterol fractions were calcu-
lated using the Friedwald equation [28].
Glucocorticoid receptors
Blood for studying glucocorticoid receptors (GR) was
drawn by three Vacutainer ® tubes with EDTA. Blood
mononuclear cells (lymphocytes and monocytes) were
isolated by the protocol described by Ulmer and Flad
[29]. The cells extracted were stored in Eppendorf tubes
with a preserving solution and kept in a freezer at -80 °C
until sent to the “Dipartimento di Scienze Farmacolo-
giche Biomolecolari, Università di Milano, Sezione di
Biomedicina ed Endocrinologia” for analysis. For West-
ern Blotting analysis the cellular lysates were resolved on
7.5 % SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), and transferred onto a nitrocellulose membrane.
GR protein was visualized with GR rabbit polyclonal anti-
body (M-20, Santa Cruz Biotechnology, Santa Cruz, Calif.,
USA), diluted 1:100 [30]. Samples from the last six partici-
pants – four women and two men – were analyzed.
Statistical analysis
A correlation analysis between variables was conducted
using Pearson’s correlation coefficient (two-tailed) test.
All the characteristics measured, expressed as differences
from baseline, were compared after 16 weeks of inter-
vention using the unpaired Wilcoxon test or Student t
test, according to the absence or presence of normality,
respectively, and evaluated by the Kolmogorov-Smirnov
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tical Analysis System software, version 9.1 (SAS Institute
Inc., Cary, NC, USA), with statistical significance ≤ 0.05,
two-tailed.
Results
Sixteen subjects were included. Of these, nine were men
and seven, women. Their average age was 34.6 SD 7 years
(ranging from 19 to 49 years old), but the evaluation of
glucocorticoid receptors was conducted in six patients–
four men and two women. They were the last six partici-
pants included in the study.
Table 1 shows the level of serum cortisol in basal con-
ditions and after suppression by dexamethasone, as well
as glucocorticoid receptors in lymphocytes and mono-
cytes. Basal cortisol levels were not altered after treat-
ment (p = 0.24). A significant decrease occurred after the
use of dexamethasone before (p < 0.001) and after treat-
ment (p = 0.01). Cortisol levels after dexamethasone
were higher after treatment (p = 0.02). Anthropometric
and laboratory analysis were not different from that of
the whole group. The glucocorticoid receptor expression
did not change after diet and metformin use as com-
pared to baseline (p = 0.66).
Table 2 shows the correlation coefficient of selected
variables and basal cortisol level, post-dexamethasone
cortisol level and number of glucocorticoid receptors in
lymphocytes and monocytes in basal conditions and
after 16 weeks of intervention. A positive correlation
was observed between BMI and basal cortisol (r = 0.50;
p = 0.05) after treatment. Glucocorticoid receptors levels
before treatment were strongly and positively correlated
with BMI (r + 0.88; p = 0.02) and insulin AUC (r +0.94;
p = 0.005). After intervention, there were no correlations
with BMI (r -0.19; p = 0.71) and the correlation with in-
sulin AUC became negative and non-statistically signifi-
cant (r -0.72; p = 0.27). There were significant negative
correlations between cortisol responses to dexametha-
sone and triglycerides (r - 0.68; p = 0.05) and VDLc (r –
0.67; p = 0.05). These correlations were also found after
treatment (r - 0.56; p = 0.04 and r - 0.55; p = 0.04). ATable 1 Cortisol levels in basal conditions and after suppression by
monocytes at baseline and 16 weeks after a hypocaloric low glycem
Variables Baseline
Mean SD
Basal cortisol (μg/dL) 7.19 b 3.35
Post-dexamethasone cortisol (μg/dL) 4.27 b 2.85
Glucocorticoid receptors d 23,390 8052
Data are expressed as mean and standard deviation (SD)
a16 weeks vs. basal = paired Student t test
bp < 0.001 basal cortisol vs. post-dexamethasone cortisol = paired Student t test
cp = 0.01 basal cortisol vs. post-dexamethasone cortisol =Wilcoxon test
dn = 6 subjects (4 male, 2 female)relevant positive correlation of insulin (r + 0.76; p =
0.08), HOMA-IR (r + 0.78; p = 0.07), HOMA2- % β (r +
0.75; p = 0.09) and a negative correlation of HOMA2- %
S (r - 0.75; p = 0.07) was observed with the glucocortic-
oid receptors in basal conditions, even if the values did
not reach the level of statistical significance.
There were no significant correlations among cortisol
and glucocorticoid receptor levels with body weight,
waist circumference, body fat, total cholesterol, HDLc,
and LDLc (data not shown).
Discussion
The epidemic rise of obesity and type-2 diabetes world-
wide is partly due to the excessive intake of inadequate
nutrients and little physical activity [2]. Before the onset of
type-2 diabetes, predisposed individuals develop pre-
diabetic conditions that lead to the disease. The progres-
sion to diabetes is weak for subjects with impaired fasting
glucose, intermediate for those with impaired glucose tol-
erance and strong for those with both conditions [2].
In this study, overweight or obese individuals with im-
paired glucose tolerance were treated with metformin
and a hypocaloric low glycemic index diet for four
months. The clinical results of the therapeutical associ-
ation of the diet and metformin in these patients were
previously published. The treatment produced a signifi-
cant decrease in body weight, BMI, waist circumference,
and body fat over the follow-up period. No change in
physical activity was observed during the intervention
weeks. In addition, a significant reduction in CI, HOMA2-
% β, triglycerides, and VLDL levels was observed [31].
The homeostatic model assessment (HOMA) [20]
used to quantify insulin resistance and beta-cell function
indicates that the treatment has produced a reduction of
the beta-cell function (HOMA2- % β), which was no
longer required to secrete a greater amount of insulin
since insulin sensitivity was increased, as shown by a
higher Cederholm Index (CI) [22].
Cortisol secretion in these pre-diabetic subjects was
tested evaluating plasma cortisol and utilizing the low
doses of dexamethasone suppression test in an attemptdexamethasone; glucocorticoid receptors in lymphocytes and
ic index diet and metformin use in 16 subjects
16 weeks Δ p a
Mean SD
8.69 c 4.55 1.50 0.24
5.99 c 5.31 1.72 0.02
26,650 9408 3260 0.66
Table 2 Pearson correlation of selected variables and basal cortisol level, post-dexamethasone cortisol level and number of
glucocorticoid receptors in lymphocytes and monocytes in basal conditions and 16 weeks after a hypocaloric low glycemic index
diet and metformin use in 16 subjects
Variables Basal cortisol Post-dexamethasone cortisol Glucocorticoid receptorsb
Basal 16 weeks Basal 16 weeks Basal 16 weeks
r p r p r p r p r p r p
BMI a -0.44 0.09 0.50 0.05 0.28 0.80 0.35 0.22 0.88 0.02 -0.19 0.71
Glucose 0.39 0.14 -0.22 0.42 -0.33 0.38 -0.02 0.94 -0.59 0.22 -0.48 0.33
AUC glucosea -0.04 0.87 -0.19 0.49 -0.49 0.11 -0.49 0.07 -0.50 0.31 0.53 0.27
Insulin -0.21 0.43 -0.24 0.37 0.54 0.91 -0.11 0.71 0.76 0.08 -0.44 0.38
AUC insulina -0.20 0.45 -0.31 0.24 0.08 0.89 -0.21 0.46 0.94 0.005 -0.72 0.27
Cederholm index 0.06 0.83 0.11 0.68 0.15 0.74 0.38 0.18 -0.53 0.28 0.38 0.46
HOMA2-IRa -0.21 0.45 0.06 0.83 0.50 0.96 0.27 0.37 0.78 0.07 -0.58 0.23
HOMA2-%βa -0.38 0.16 0.17 0.54 0.56 0.57 0.09 0.76 0.75 0.09 -0.45 0.37
HOMA2-%Sa 0.01 0.97 -0.25 0.37 -0.40 0.50 -0.47 0.10 -0.75 0.07 0.75 0.09
Triglyceride -0.10 0.72 -0.37 0.16 -0.68 0.05 -0.56 0.04 0.05 0.92 0.16 0.76
VLDL-ca -0.09 0.73 -0.36 0.17 -0.67 0.05 -0.55 0.04 0.03 0.95 0.17 0.74
aAbbreviations: BMI = body mass index; AUC glucose = area under the glycaemic curve; AUC insulin = area under the insulinaemic curve; HOMA2-%β = homeostasis
model assessment β-cell function; HOMA2-IR = homeostasis model assessment insulin resistance; HOMA2-%S = homeostasis model assessment insulin sensitivity;
VLDL-c = very low density lipoprotein cholesterol
b6 subjects (4 male and 2 female)
Casulari et al. Diabetology & Metabolic Syndrome  (2015) 7:65 Page 5 of 7to detect subtle changes in the feedback of cortisol con-
trol in the hypothalamus and pituitary gland. Cortisol
levels and physiological cortisol suppression occurred in
response to low doses of dexamethasone, before and
after intervention, in agreement with previous investiga-
tions conducted to verify normal and abnormal secretion
of this hormone [9, 10, 19]. We can infer from these re-
sults that cortisol secretion is preserved in obese individ-
uals in pre-diabetic condition.
The HPA axis activity in obese and type 1 diabetic pa-
tients has been investigated in several studies with con-
flicting results. In obese individuals cortisol levels have
been reported to be normal [32, 33], while in other stud-
ies fasting and postprandial cortisol secretion in obese
patients has been described as lower than in lean sub-
jects [34]. In agreement with the findings of this study
several authors [10, 12, 14] have reported normal corti-
sol suppression tests in response to low doses dexa-
methasone in obese individuals.
In patients with type 2 diabetes the hypothalamic
pituitary-adrenal (HPA) axis activity appears increased in
most studies: elevation of ACTH [35, 36], of basal [35, 37,
38] and suppressed serum cortisol (after dexamethasone
test) [39, 40] and of late-night salivary cortisol levels [41]
have been reported. In particular the presence of chronic
complications of type 2 diabetes (i.e., macroangiopathy,
retinopathy, and neuropathy) have been associated to with
HPA axis overactivity [37, 42–47].
The corticosteroid receptor density measured in a subset
of our patients in leukocytes does not show a significant
variation between the pre and post-treatment conditions.To the authors’ knowledge a single paper is available in the
literature on the relationships between insulin secretion,
insulin resistance and corticosteroid receptors. In agree-
ment with the results of the study here presented, Islam
et al. [16] reported, in a study including 78 normo or
slightly hyperglycemic subjects, that glucocorticoid recep-
tor concentration in leukocytes is significantly and posi-
tively correlated with insulin resistance and BMI.
However, it is worth of note that there is a strong cor-
relation between corticosteroid receptors and insulin
AUC, BMI and, to a minor extent, insulin levels and in-
sulin resistance in the pre-treatment period, when the
insulin secretion was increased. After metformin and
hypocaloric diet treatment, when insulin sensitivity
improved, this correlation disappears. The beneficial
effect of this type of metformin and hypocaloric diet
treatment in improving insulin sensitivity was also de-
scribed in two previous articles by some of the au-
thors of our research group. In the first one, quoted
above, metformin and hypocaloric diet showed benefi-
cial effects in anthropometric and metabolic parame-
ters of the same group of subjects with impaired glucose
tolerance [31]. In the second study, an increase in the
levels of total and free testosterone was observed in sub-
jects with hypogonadotropic hypogonadism with meta-
bolic syndrome [48].
The mechanisms involved in metformin hypoglycemic
action in diabetic or glucose intolerant subjects are still
unknown [49–51]. Metformin has a glucose lowering ef-
fect related to reduction in hepatic gluconeogenesis. The
action is partially related to antagonism to glucagon
Casulari et al. Diabetology & Metabolic Syndrome  (2015) 7:65 Page 6 of 7activity [49], but also to stimulation of 5’-AMP-activated
protein kinase, which confers insulin sensitivity, mainly
by modulating lipid metabolism [49–51]. Recently, it has
been shown that oral administration of 1000 mg of met-
formin causes cortisol metabolite fluctuation, indicating
that the neuroendocrine system may be involved in met-
formin’s antidiabetic effect [51]. There is in vitro and
in vivo evidence that the antidiabetic effects of metfor-
min are related to the gluconeogenetc actions of cortisol
action. It has been proposed that the mechanism in-
volved is a reduction of POMC/adrenocorticotropic hor-
mone/cortisol levels following AMPK/liver X receptor α
phosphorylation in the pituitary [51].
Conclusion
Cortisol secretion was not altered in this group of pa-
tients with impaired glucose tolerance, and treatment
did not change this condition. However, glucocorticoid
receptors are strongly correlated with insulin secretion
and lose this characteristic after treatment.
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